Navigation Links
First Warning Systems, Inc., Retains Joshua D.I. Ellenhorn, M.D., as Principal Investigator
Date:8/26/2013

patented time sequenced profile which correlates to circadian cellular processes expressed through specific circadian genotypes. Multiple bioinformatics algorithms compare the circadian gene expression profiles to identify breast tissue abnormalities at different stages of development of disturbed breast tissue cells. FWS delivers an objective Clinical Decision Support Service report to the primary care physician with industry leading accuracy.

About First Warning Systems
First Warning Systems, (FWS) founded in 2008, is based in Reno, Nev. The FWS product line is a device and software service that detects breast tissue abnormalities leading to health risk assessment and management including early breast cancer identification. Three clinical trials with over 650 participants have achieved proof of concept and superior outcomes when compared to other diagnostic protocols. FWS’ technology is exclusively licensed for development, manufacturing and marketing worldwide from Lifeline Biotechnologies, Inc (OTC Market: LLBO). FWS is planning a final, limited clinical trial and a 510k device classification to validate the fourth generation of the FWS product. FWS is preparing to apply for a Euro CE Mark to market in the European Union and Asia Pacific markets. See FWS’ video, “Breast Cancer Tumor Progression” at http://www.firstwarningsystems.com/.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11059852.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
3. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
4. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
5. Webcor Builders Selected as the General Contractor for First Phase of LA BioMeds New Campus Master Plan
6. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
7. Tiger Woods Gives Exclusive First Interview Since POWERED by FUSE Announcement!
8. The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics
9. Eye Surgery Center of Michigan First in Southeast Michigan to Perform Bladeless Cataract Surgery Using New LenSx® Laser Technology
10. Amgen Announces 2012 First Quarter Dividend
11. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 26, 2015 Research ... of the "Global Breast Cancer Monoclonal Antibodies ... Globally, Roche seems to dominate the ... inventory. Its block buster molecule, Herceptin has been ... It was found that breast cancer cells become ...
(Date:5/27/2015)... Fla. (PRWEB) May 27, 2015 Expanding ... dental cement manufacturer Avalon Biomed Inc. recently ... of Mokuda Dental Co. Ltd. , the largest ... inroad into the international market for Avalon Biomed, which ... Plus®, award-winning tricalcium silicate-based dental cements that have won ...
(Date:5/27/2015)... Israel , May 27, 2015  Tikcro Technologies ... quarter ended March 31, 2015. ... quarter, we continued pre-clinical work to generate functional specific ... an early stage, we are encouraged by the development ... field as new antibodies which modulate immune checkpoints gain ...
(Date:5/27/2015)... MB (PRWEB) May 27, 2015 ... data to combat disease, Cubresa Inc. today announced ... “Our MR Compatible in-bore PET Scanner uses silicon ... into single-purpose preclinical MRI machines from manufacturers like ... Cubresa, headquartered in Winnipeg, Canada. “This enables simultaneous ...
Breaking Biology Technology:Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 2Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 3Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3Cubresa Launches Simultaneous PET/MRI Technology 2
... , SAN DIEGO , INDIANAPOLIS and WALTHAM, Mass. ... AMLN ), Eli Lilly and Company (NYSE: LLY ) and ... and Drug Administration (FDA) has classified the BYDUREON™ (exenatide for extended-release injectable ... Prescription Drug User Fee Act (PDUFA) action date of October 22, ...
... , May 6 /PRNewswire-FirstCall/ - Aeterna Zentaris ... drug development company specialized in oncology and endocrinology, today ... and Drug Administration (FDA), orphan-drug designation for AEZS-108, its ... cancer. AEZS-108 is currently in a Phase 2 trial ...
... Belgium and LUND, Sweden , May 6, 2010 , ... - TB-402 Demonstrates Superior Antithrombotic ... ThromboGenics ... from,their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant,that is ...
Cached Biology Technology:BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 2BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 3BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 4BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 5BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 6BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 7BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 8Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer 2Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer 3ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402) 2ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402) 3ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402) 4ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402) 5ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402) 6ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402) 7
(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
(Date:5/14/2015)... , May 14, 2015  Verificient ... identity verification and online remote proctoring, announced ... software-as-a-service (SaaS) company and creator of the ... of the two companies will benefit from ... Canvas. As a fully integrated ...
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... life forms that have been around since the dinosaurs, ... because they can simultaneously produce other valuable products ... Engineers at Oregon State University concede that such ... not science fiction many of the needed advances ...
... tested a new technique to ensure fresh produce is free ... particles created when gases are excited by an energy source. ... research shows, some can hide from its effects in the ... and vegetables is promoted as part of a healthy lifestyle, ...
... National Heart, Lung, and Blood Institute, part of the ... to Albert Einstein College of Medicine ... study of hemoglobin toxicity that may complicate blood transfusions ... goals include making blood transfusions safer and more effective ...
Cached Biology News:Ancient diatoms could make biofuels, electronics and health food -- at the same time 2Assessing a new technique for ensuring fresh produce remains Salmonella-free 2Einstein researcher receives $10.8 million grant to study toxic blood reactions caused by hemoglobin 2
... EZ-Spread Plating Beads Sterile plating in ... glass rods and potentially hazardous ethanol flaming, ... choices of ready-to-use sterile packaging: dispenser bottle for ... plating, Fastest and easiest way to ...
... in a regulated environment, Pipette Tracker ... software that automates gravimetric pipette calibration ... that meets todays regulatory compliance requirements. ... solution that includes a full security ...
... (RTL) can provide you with the ... method development and validation ,Performance of ... of your GMP manufacturing environment ,Assurance ... a full spectrum of microbiological services ...
... IgY) , After we receive your antigen (see ... appropriate number of chickens and begin to collect ... (usually over a period of 3-5 days), we ... of four injections into the breast muscle. The ...
Biology Products: